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ABSTRACT (254 words) 
Objectives: Pregabalin, an α2-δ agonist, is approved for the treatment of fibromyalgia (FM) 
in the United States, Japan, and 37 other countries. The purpose of this article was to provide 
an in-depth, evidence-based summary of pregabalin for FM as demonstrated in randomized, 
placebo-controlled clinical studies, including open-label extensions, meta-analyses, 
combination studies, and post-hoc analyses of clinical study data. 
Methods: PubMed was searched using the term ‘pregabalin AND fibromyalgia’ and the 
Cochrane Library with the term ‘pregabalin’. Both searches were conducted on 2 March 2017 
with no other date limits set. 
Results: Eleven randomized, double-blind, placebo-controlled clinical studies were identified 
including parallel group, 2-way crossover, and randomized withdrawal designs. One was a 
neuroimaging study. Five open-label extensions were also identified. Evidence of efficacy 
was demonstrated across the studies identified with significant and clinically relevant 
improvements in pain, sleep quality, and patient status. The safety and tolerability profile of 
pregabalin is consistent across all the studies identified, including in adolescents, with 
dizziness and somnolence the most common adverse events reported. These efficacy and 
safety data are supported by meta-analyses (13 studies). Pregabalin in combination with other 
pharmacotherapies (7 studies) is also efficacious. Post-hoc analyses have demonstrated the 
onset of pregabalin efficacy as early as 1–2 days after starting treatment, examined the effect 
of pregabalin on other aspects of sleep beyond quality, and shown it is effective irrespective 
of the presence of a wide variety of patient demographic and clinical characteristics.  
Conclusions: Pregabalin is a treatment option for FM; its clinical utility has been 
comprehensively demonstrated. 
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Introduction  
Fibromyalgia (FM) is a chronic pain disorder that affects ~1%–10% of the general adult 
population [1]. Prevalence rates vary by country, age, gender, education levels, and 
socioeconomic status, and may further depend on disease awareness, diagnosis rates, 
methodology, and diagnostic criteria [1-12]. FM can be considered a prototypical centralized 
pain state resulting in augmented central pain processing [13]. Neuroimaging studies have 
documented changes to the pain processing systems associated with FM including the brain 
activation patterns associated with pain augmentation [14,15], alterations to functional 
connectivity [16-18], and aberrant neurotransmitter systems, including glutamatergic 
neurotransmission [19-21]. A ‘neurophysiological signature’ for FM may exist [22]. In 
addition to chronic widespread pain, FM may also be characterized by multiple symptom 
domains including sleep disturbance, fatigue, anxiety, depression, and cognitive dysfunction 
[2,23,24], all of which can negatively impact patients’ function and generate a significant 
clinical burden [25-28].  
 
The clinical heterogeneity of FM has led to the development of multiple therapeutic options, 
including pharmacological and non-pharmacological treatments [29,30]. Treatments 
generally ameliorate symptoms rather than eliminating them. Pregabalin is an α2-δ calcium 
channel subunit ligand [31], but its mechanism of action in FM is not fully elucidated. As 
noted above, aberrant glutamatergic neurotransmission has been implicated in FM 
pathophysiology [13], and elevated levels of glutamate have been reported in specific brain 
regions associated with chronic pain, notably the insula [19]. Pregabalin may target this 
aberrant glutamatergic neurotransmission. Binding of pregabalin to the α2-δ subunit reduces 
calcium influx into the pre-synaptic terminal thereby impeding glutamate release [32,33].  
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Pregabalin is approved for the pharmacological management of FM in the United States (US) 
[34], Japan, and 37 other countries. Milnacipran and duloxetine are also approved 
pharmacological treatments of FM in the US [35,36]. National and international FM 
management guidelines recommend pregabalin for the treatment of FM [37-41]. The 
approvals of pregabalin and recommendations for FM treatment are based on a clinical trial 
program that demonstrated its efficacy and safety in multiple randomized, placebo-controlled 
clinical studies [42-47]. Using the patient data from these clinical studies, post-hoc analyses 
have been conducted to further explore the effectiveness and safety of pregabalin for FM. 
Systematic review and meta-analysis techniques have also examined the efficacy and safety 
of pregabalin, and poly-drug therapy involving pregabalin and other pharmacological 
treatments has been clinically evaluated. As a result, there is a large body of evidence 
assessing pregabalin for the treatment of FM. The purpose of this article was to provide an in-
depth, evidence-based summary of the clinical studies, including combination studies, meta-
analyses, and post-hoc analyses that have evaluated pregabalin for the treatment of FM. 
 
Materials and Methods 
PubMed was searched using the search term ‘pregabalin AND fibromyalgia’ on 2 March 
2017. A search of the Cochrane Library database using the term ‘pregabalin’ was also 
conducted on the same date. For both searches, no other date limits were set but identified 
articles were limited to the English language. We also examined reference lists in identified 
articles and personal lists of references for additional items, as well as drawing upon personal 
knowledge of recently completed studies. Articles that assessed pregabalin clinical studies, 
meta-analyses, combination studies, and post-hoc analyses of pregabalin clinical data were 
evaluated. Identified studies included both pregabalin immediate release (IR) and controlled 
release (CR) formulations. Clinical studies were included if they were double-blind, placebo- 
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or comparator-controlled randomized trials, as they represent the gold standard for reporting 
clinical data. All identified randomized, controlled studies were included irrespective of the 
type of primary endpoint or evaluation. Open-label extension studies of randomized, 
controlled trials were included because these studies provided longer-term safety information 
for the subject evaluated in the randomized, controlled trials. Combination studies of 
pregabalin with other treatments were included, whether randomized or not. Other open-label 
studies, observational studies, and non-blinded studies were excluded. Post-hoc analyses, 
based on data captured in the randomized, controlled trials, were included if the authors 
believed they added important information to the clinical profile of pregabalin. Studies that 
had health economic or outcomes research as primary objectives were not included as part of 
this review. All the authors agreed upon the inclusion of articles. Data were reviewed to 
provide an evidence-based, clinical summary of pregabalin efficacy and safety. Different 
types of studies, eg randomized controlled trials or meta-analyses, were considered 
separately, and individual studies were summarized separately. 
 
Results  
A total of 284 items were captured in PubMed and 28 from the Cochrane Library database. 
The following sections summarize the clinical profile of pregabalin based on study type. 
Randomized, double-blind, placebo-controlled, clinical studies 
Eleven clinical studies were identified as randomized, double-blind, placebo-controlled, 
studies [42-52]. Table 1 shows a summary of the studies (see also Table 1 of the  
Supplemental Online Material for more details of each study). Studies were conducted 
globally, including in North and South America, Europe, Asia, and Australia. Six studies 
were of parallel group design, three were two-way crossover studies, and two were 
randomized withdrawal studies. Ten studies were in adults and one study was in adolescents. 
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Nine of the studies examined the efficacy and safety of the pregabalin IR capsule formulation 
at doses of 75–600 mg/day, and in one study pregabalin was assessed as a CR formulation at 
doses of 330 and 495 mg/day. One study was a neuroimaging study of pregabalin at a dose of 
450 mg/day that examined changes in brain area connectivity and neurochemical alterations 
in patients with FM following pregabalin treatment. In seven of the studies, the primary 
efficacy endpoint was the placebo-adjusted change in mean pain score from baseline, based 
on an 11-point numeric rating scale (NRS), ranging from 0 (no pain) to 10 (worst possible 
pain). The primary efficacy endpoint in the randomized withdrawal trials was the time to loss 
of therapeutic response (LTR). One study [48] evaluated pregabalin in adult FM patients with 
disrupted sleep utilizing polysomnography (PSG) for the primary efficacy endpoint of wake 
after sleep onset (WASO). Mean pain score and sleep quality score, both reported on an 11-
point NRS, were also captured as secondary efficacy endpoints during this study. In the 
neuroimaging study [49], the primary efficacy evaluation was the voxel-wise blood oxygen 
level dependent brain activation signal assessed using functional magnetic resonance imaging 
(fMRI). Of note, some authors are involved in a randomized, placebo-controlled study in a 
Chinese FM population that has recently completed and results are pending. Importantly, the 
following sections include findings from positive and negative trials, and report positive and 
negative efficacy endpoints. 
 
Mean pain scores 
A comparison of the placebo-adjusted mean pain scores at the end of treatment for the 
parallel group and crossover studies is summarized in Table 2 and shown in Figure 1A. For 
the crossover studies, data from the different treatment periods were analyzed using standard 
crossover design methods to produce the efficacy endpoint estimate. Pregabalin numerically 
improved mean pain score relative to placebo in all the treatment arms across all the studies, 
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and was statistically significant in 11 arms. Placebo-adjusted improvements in mean pain 
score ranged from –0.33 to –0.98 for doses of 300 and 450 mg/day. The magnitude of the 
response was comparable in adults and adolescents, although the improvement in mean pain 
score relative to placebo was not significant in adolescents. With the exception of the 
adolescent trial, in all the other studies, significant improvement for pregabalin over placebo 
occurred during the first week of treatment, demonstrating rapid onset of pain reduction. 
Pregabalin was generally found to maintain significant improvement over placebo at each 
week through the duration of the study. 
 
Secondary endpoints 
The effects of pregabalin versus placebo on commonly assessed secondary evaluations at the 
end of treatment are summarized in Table 2 and shown in Figure 1B and C (see also Figure 1 
of the Supplemental Online Material). Endpoints include sleep quality, Patient Global 
Impression of Change (PGIC) responder rates, 30% and 50% pain responder rates, 
Fibromyalgia Impact Questionnaire (FIQ) total score, Multidimensional Assessment of 
Fatigue (MAF) global index, and Hospital Anxiety and Depression Scale-Anxiety (HADS-A) 
and -Depression (HADS-D). In general, pregabalin numerically and consistently improved 
scores for these secondary evaluations relative to placebo, with many, but not all, statistically 
significant (Table 2). The data for doses of 300 and 450 mg/day are summarized below. 
Improvements in sleep quality, scored on an 11-point NRS, were consistently significantly 
better with pregabalin than placebo (Figure 1B). In six studies, sleep quality was scored from 
0 = best possible sleep to 10 = worst possible sleep and scores ranged from –0.48 to –1.31 
relative to placebo. In two studies, sleep quality scores were reversed (0 = worst possible 
sleep and 10 = best possible sleep) and pregabalin was also significantly better than placebo 
in both of them. Note that in Figure 1B, the direction for Roth et al. 2012 and Arnold et al. 
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2015 is the same as for the other studies to enable consistent interpretation of the data. PGIC 
scores were also consistently significantly better with pregabalin than placebo (Figure 1C). 
The proportion of patients who were PGIC responders, i.e., whose symptoms were ‘much 
improved’ or ‘very much improved’, ranged from 31.9% to 51.6%, compared with 23.5%–
34.8% with placebo. The proportion of 30% pain responders, i.e., those patients with a ≥30% 
improvement in mean pain score, ranged from 32.6% to 49.5% compared with 18.5%–34.7% 
for placebo (Supplemental Online Material Figure 1). The proportion of 50% pain responders 
ranged from 17.9% to 28.9% for pregabalin compared with 9.2%–20% for placebo 
(Supplemental Online Material Figure 1). Placebo-adjusted improvements in FIQ total scores 
(scored from 0 to 100, with higher scores indicating greater impact) ranged from –1.17 to –
6.60 (Supplemental Online Material Figure 1). MAF was assessed in four studies and 
improvements with pregabalin were rarely significantly better than placebo (Supplemental 
Online Material Figure 1). HADS-A and HADS-D scores with pregabalin were rarely 
significantly better than placebo (Supplemental Online Material Figure 1). The effect of 
pregabalin on these secondary endpoints was comparable in adults and adolescents.  
 
Polysomnography study  
In the crossover PSG study the primary efficacy endpoint was WASO and secondary efficacy 
evaluations mostly focused on other PSG measures [48] (see Table 1 of the Supplemental 
Online Material for more details of the study). Relative to placebo, pregabalin significantly 
decreased WASO at the end of the study (–19.33 min; p < 0.001) (Table 2). Of the other PSG 
items, compared with placebo, pregabalin also significantly improved the total sleep time 
(TST), sleep efficiency, the number of awakenings after sleep onset, wake time during sleep, 
the latency to persistent sleep, and amount of slow wave sleep, but not wake time after sleep. 
Sleep was also assessed using a patient-reported subjective sleep questionnaire in this study. 
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Of the subjective items, pregabalin significantly improved WASO, TST, latency to sleep 
onset, and sleep efficiency compared with placebo at the end of study treatment. Sleep quality 
was also better with pregabalin than placebo in this study (Figure 1B).  
 
Randomized withdrawal studies 
In the two randomized withdrawal studies, the primary efficacy endpoint was the time to 
LTR (see Table 1 of the Supplemental Online Material for more details of these studies 
including definitions of LTR for each study). In Crofford et al. 2008 [44], the time to LTR 
was significantly longer for patients treated with pregabalin than placebo (p < 0.001) (Table 
2). Median time to LTR was 19 days for placebo but was not reached for pregabalin because 
half the group had not lost their therapeutic response by the end of the study (26 weeks of 
double-blind treatment). In addition, individual pregabalin doses of 300, 450, and 600 mg/day 
were associated with a significantly longer time to LTR compared with placebo-treated 
patients (all p < 0.001). All secondary efficacy evaluations, including PGIC, FIQ total score, 
Medical Outcomes Study-Sleep Scale (MOS-Sleep Scale), and MAF, showed significantly 
longer times to LTR for all doses of pregabalin combined than placebo (all p < 0.001). In 
Arnold et al. 2014 [50], the median time to LTR during the double-blind phase was 
significantly longer for pregabalin than placebo (58 vs. 22 days; p < 0.05) (Table 2). 
Treatment differences for the secondary efficacy evaluations of mean pain score, 30% and 
50% pain responder rates, PGIC, FIQ total score, HADS-D, sleep quality, and MOS-Sleep 
Scale were better for pregabalin compared with placebo, but not significantly.  
 
Neuroimaging study 
The randomized, placebo-controlled neuroimaging study [49] used a series of three 
complementary brain imaging techniques, proton magnetic resonance spectroscopy, fMRI, 
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and functional connectivity magnetic resonance imaging, to assess the clinical action of 
pregabalin versus placebo in alleviating FM pain (briefly summarized in Table 1; see Table 1 
of the Supplemental Online Material for more details of the study). The study tested the 
hypothesis that pregabalin was exerting its effect by modulating glutamatergic activity in key 
brain regions involved in pain processing, such as the insula, and that by doing so it reduced 
aberrant connectivity between the insula and networks such as the default mode network 
(DMN) [16,17,19,21]. These a priori hypotheses were largely borne out. Pregabalin but not 
placebo reduced combined glutamate/glutamine levels in the posterior insula. Pregabalin-
related pain relief was associated with reduced connectivity between the posterior insula and 
the DMN, and pregabalin but not placebo reduced the response of the DMN to experimental 
pain. This study also appeared to identify neuroimaging markers for pregabalin responses. 
Higher pre-pregabalin glutamate/glutamine levels in the posterior insula and greater resting 
state connectivity from the insula to the DMN both predicted the subsequent analgesic 
response to pregabalin, but not placebo. 
 
Safety and tolerability 
Table 3 summarizes the safety and tolerability data from the 11 clinical studies described 
above (see also Supplemental Online Material Figure 2). Data for doses of 300 and 450 
mg/day, including flexible 300–450 mg/day dosing, and corresponding placebo treatment 
arms are included below. The proportion of patients reporting an adverse event (AE) ranged 
from 77.3% to 91.8%, compared with 59.9%–77.1% for placebo. Serious AEs (SAEs) 
occurred infrequently with pregabalin (range 0.6%–4.4%), similar to placebo (range 0.4%–
2.2%). Discontinuations due to AEs varied considerably for pregabalin (range 6.1%–22.4%) 
and were more common compared with placebo (range 3.4%–10.9%). The incidences of the 
most commonly occurring AEs were generally dose dependent, with the exception of 
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headache which occurred at rates similar to placebo (Supplemental Online Material Figure 2). 
Dizziness and somnolence were the most commonly reported AEs and were also the most 
common AEs leading to discontinuation. The safety profile of pregabalin was similar in 
adolescents and adults, although the incidence of somnolence was lower in adolescents and 
incidences of nausea and fatigue were higher (data not shown) [52]. AE duration was 
reported for a limited number of patients in two studies [42,43]. In Crofford et al. 2005 [42], 
the median duration of dizziness dose-dependently increased from 6 days to 15 days for 300 
mg/day and 450 mg/day, respectively. Conversely, the median duration of somnolence dose- 
dependently decreased from 21 days to 18 days for the same doses. In Mease et al. 2008 [43], 
the median duration of dizziness dose-dependently increased from 19 days to 28 days for 300 
and 450 mg/day, respectively. By comparison, the median duration of somnolence dose- 
dependently decreased from 88 days to 79.5 days for the same doses. The median durations 
of weight gain increased from 64 days to 69.5 days for 300 and 450 mg/day, respectively.  
 
Five studies [43,45-47,52] had open-label extensions with the main objective of examining 
long-term safety and tolerability [52-54]. Pooled data from three studies showed that for up to 
1 year of treatment at doses up to 600 mg/day, 77.9% of patients reported an AE and 12.4% 
discontinued treatment owing to an AE [53]. SAEs occurred rarely, with only three patients 
reporting pregabalin-related SAEs. The most commonly reported AEs were dizziness, 
somnolence, headache, peripheral edema, and weight gain. In the 1-year open-label extension 
in Japanese patients, 96.2% of patients reported an AE, 2.8% reported a SAE, and 4.7% 
discontinued due to AEs [54]. The most common AEs were nasopharyngitis, somnolence, 
dizziness, constipation, and weight gain. In the 6-month open-label extension in adolescents, 
71.4% experienced an AE, 4.8% experienced a SAE, and 3.2% discontinued treatment owing 
to AEs [52]. The most frequent AEs were weight gain, dizziness, fatigue, and headache. 
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Other randomized, double-blind, clinical studies 
One additional study of pregabalin monotherapy was identified, a double-blind, randomized 
8-week trial that compared once-nightly versus twice-daily administration of pregabalin (300 
mg/day) in 177 patients not currently taking pregabalin [55]. The within-treatment 
improvement in mean pain score (11-point NRS) relative to baseline was significant for both 
once-nightly and twice-daily pregabalin (both p < 0.001). No differences were observed 
between treatment groups. Improvements in secondary efficacy endpoints including 30% and 
50% pain responder rates, revised FIQ scores, fatigue scores, sleep disturbance scores, and 
PGIC were also similar between the two groups. The number of patients who withdrew due 
to AEs was similar in the two treatment arms, but significantly more patients in the twice-
daily group reported AEs compared with the once-nightly group (p < 0.05) The incidences of 
individual AEs were comparable in the two groups. Once-nightly dosing may therefore 
convey some safety and tolerability advantages over twice-daily dosing, with no adverse 
impact on efficacy.  
 
Meta-analyses  
Thirteen meta-analyses that assessed pregabalin for FM were identified [56-68]. One meta-
analysis [56] was excluded because it showed data from the individual treatment arms of 
individual clinical studies and therefore provided no additional information to that presented 
above. We also excluded a second meta-analysis [68] because it was an indirect comparison 
of pregabalin efficacy and tolerability with that of duloxetine and milnacipran, and did not 
present data on pregabalin alone. Eleven meta-analyses that evaluated the efficacy and 
tolerability of pregabalin versus placebo were examined further (summarized in Table 1; see 
Table 2 of the Supplemental Online Material for more details of each meta-analysis) [57-67]. 
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Ten studies analyzed pain responses, typically 30% and 50% pain responder rates, and eight 
studies analyzed other efficacy endpoints, most commonly PGIC. Seven studies analyzed 
tolerability, specifically withdrawals due to AEs. One study assessed tolerability alone with 
no efficacy analysis. Most studies analyzed individual doses of pregabalin. Data on 
pregabalin at the dose of 150 mg/day is not reported here since that was used in only one 
treatment arm of one study [42]. However, some studies combined all pregabalin doses for 
analysis, including 150 mg/day. Not all analyses reported statistical significance. 
 
In summary, the findings of the meta-analyses support the findings of the individual clinical 
studies (see Table 2 of the Supplemental Online Material for more details). All individual 
doses of pregabalin (300, 450, and 600 mg/day, as well as flexible 300–450 mg/day dosing) 
showed a benefit in improving pain versus placebo. Pregabalin also improved PGIC scores 
and sleep disruption compared with placebo irrespective of dose, also in agreement with the 
individual clinical studies. The meta-analyses also revealed that fatigue, depression, anxiety, 
and FIQ total scores were improved with pregabalin versus placebo, generally significantly 
[58,61,65]. This is in contrast to the majority of the individual clinical studies, and 
presumably occurs because of the increased power to detect a difference between pregabalin 
and placebo. The meta-analyses also demonstrated a greater risk for withdrawals due to AEs 
for pregabalin compared with placebo, similar to the individual clinical studies.  
 
Combination studies 
A total of seven combination studies involving pregabalin were identified (summarized in 
Table 1; see also Table 3 of the Supplemental Online Material for more details of each 
individual study) [69-75]. The placebo-controlled clinical study in which pregabalin was 
added on top of an antidepressant [51] because has been discussed in detail above as the 
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antidepressant was being administered for the treatment of depression alone and not FM. The 
types of studies varied considerably from a randomized, double-blind, placebo-controlled 
trial to open-label, uncontrolled studies. However, because combination studies involving 
pregabalin treatment are uncommon, and poly-drug therapy is a promising area of research, 
we included all the studies for discussion.  
 
Invariably, pregabalin in combination with another FM treatment improved treatment 
outcomes, whether related to pain or other symptom domains, compared with placebo or 
either treatment when administered alone (Supplemental Online Material Table 3). Based on 
withdrawals due to AEs, the tolerability of pregabalin in combination with another treatment 
was no worse when compared with placebo or either treatment when administered alone. It is 
worth noting that the majority of studies discussed here were conducted in relatively small 
patient populations, with some exceptions [71,73]. Nonetheless, these studies provide a 
platform for future large-scale, randomized, placebo- or comparator-controlled, double-blind 
trials of pregabalin in combination with other treatments. 
 
Post-hoc analyses of clinical studies 
Clinical aspects of the effectiveness and safety of a drug may only become apparent outside 
the confines of a single study, or when studies are pooled to create larger patient databases. 
We therefore examined post-hoc analyses of the randomized, double-blind, placebo-
controlled, clinical studies to assess further the clinical effectiveness and safety profile of 
pregabalin.  
 
Clinically relevant improvement in symptoms 
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Pooled patient data from four clinical studies were used to assess the proportion of patients 
who achieved any improvement (≥0%), minimal improvement (≥15%), moderate 
improvement (≥30%), substantial improvement (≥50%), or extensive improvement (≥70%) in 
pain response and sleep quality with doses of 300, 450, and 600 mg/day pregabalin versus 
placebo [76]. For each dose of pregabalin, the proportion of patients reporting substantial or 
extensive improvement in pain increased every week from baseline until approximately week 
6, and then reached a steady state that was maintained until the end of the analysis at 12 
weeks. At 6 weeks, the proportions of patients with different levels of improvement for a 
dose of 300 mg/day were: any, 65%; minimal, 52%; moderate, 36%; substantial, 21%; and 
extensive, 7.7%. For a dose of 450 mg/day, the proportions were: any, 68%; minimal, 56%; 
moderate, 39%; substantial, 23%; and extensive, 9.0%. All levels of improvement were 
greater with pregabalin, irrespective of dose, compared with placebo. Analysis of sleep 
quality scores reported similar findings. In a pooled analysis of five clinical studies, the 
change in pain severity from baseline to endpoint was compared for pregabalin versus 
placebo [77]. Pain severity was based on the 11-point NRS mean pain score, with categories 
of severe (≥7 to ≤10); moderate (≥4 to <7); and mild (0 to <4). Patients with FM administered 
fixed doses of 300 or 450 mg/day pregabalin were significantly (p < 0.05) more likely to 
improve pain severity category, i.e., shift from severe to moderate/mild pain, or from 
moderate to mild pain, compared with placebo. The proportion of patients who shifted pain 
severity category was also numerically greater in patients who received a flexible dose of 
300–450 mg/day pregabalin compared with placebo. 
 
Sleep 
As described above, pregabalin significantly improved sleep quality versus placebo across 
studies for almost all doses of pregabalin, except 150 mg/day. A PSG study also detailed the 
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effects of pregabalin on sleep architecture [48]. Several post-hoc analyses have further 
examined other clinical effects of pregabalin on sleep. In patients with either moderate or 
severe pain at baseline, pregabalin (300–450 mg/day) statistically significantly improved 
sleep quality compared with placebo [78]. A post-hoc analysis of the PSG study showed that 
pregabalin at doses of 150–450 mg/day increased the duration of sleep bouts and decreased 
the duration of wake bouts to improve FM-related sleep disturbance [79]. Analysis of a 
subset of patients enrolled in the PSG study aimed to demonstrate that the effects of 
pregabalin observed in the laboratory were detectable at home, as measured using actigraphy 
[80]. Pregabalin significantly increased sleep efficiency and decreased sleep activity 
compared with placebo at home. A separate post-hoc analysis that pooled data from two 
clinical studies showed that pregabalin (300–600 mg/day) improved sleep dysfunction versus 
placebo primarily through a direct effect on patients’ insomnia [81].  
 
Time course of effects 
A post-hoc analysis of four clinical studies comprising 12 pregabalin treatment arms (doses 
of 150–600 mg/day) and four placebo arms determined the time to immediate and sustained 
clinical improvements in pain and sleep quality [82]. The time to immediate clinical 
improvement in pain (the first of ≥2 consecutive days for which the mean score for pain or 
sleep was statistically significantly lower for pregabalin versus placebo) was 1–2 days for the 
eight treatment arms where pregabalin was better than placebo at endpoint. For the 11 
treatment arms where sleep quality was significantly better than placebo at endpoint, the time 
to immediate clinical improvement was 1 day in all 11 treatment arms. The time to sustained 
clinical improvement in pain (≥1-point reduction in the pain or sleep score from each 
individual patient’s baseline score) was 3–6 days in the first quartile of pain responders (ie 
the first 25% of patients to respond), depending on dose, compared with 15 days for placebo. 
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Sustained clinical improvement in sleep quality occurred in 2–4 days in the first quartile of 
sleep responders, depending on dose, compared with 9 days for placebo. A second analysis of 
two clinical studies examined the time to transient and stable improvements in pain in 
patients stratified by FM severity at baseline, based on FIQ total score [83]. The median time 
to transient improvement (≥27.9% improvement in mean pain score, considered a clinically 
meaningful improvement in pain [84]) was 5–7 days for pregabalin, depending on dose, 
compared with 11–12 days with placebo. The median time to stable improvement (the mean 
of the daily improvements ≥27.9% relative to baseline over the subsequent duration of the 
study starting on the day of the transient improvement) was 13–29 days for pregabalin, 
depending on dose, compared with ≥86 days for placebo. The median time to both transient 
and stable pain improvement was correlated with baseline FM severity, with longer times to 
improvement associated with worse FM. The time course of the 30% and 50% pain response 
has been assessed in a post-hoc analysis of one study [85]. The proportion of patients 
achieving a 30% pain response with pregabalin peaked in weeks 2 and 3 after the start of 
treatment, and the proportion of patients who achieved a 50% pain response with pregabalin 
peaked by week 3 of treatment. This analysis also examined the time to appearance of some 
of the most commonly reported AEs (somnolence, dizziness, weight gain, and constipation). 
For each AE, the majority of incidences occurred within 4 weeks of starting treatment. 
Finally, a post-hoc analysis of one study examined the duration of responses across multiple 
FM symptom domains [86]. Analysis of FIQ total score, MOS-Sleep Scale, and the 36-item 
Short-Form Health Survey showed a significantly longer time to LTR for each measure for 
pregabalin versus placebo.  
 
Effect of patient characteristics at baseline on efficacy 
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A variety of post-hoc studies that pooled patient data from two or more clinical studies have 
demonstrated that the efficacy of pregabalin at a dose of 300–450 mg/day is largely 
unaffected by patient demographic and clinical characteristics at baseline. Patients had 
significantly better pain relief with pregabalin over placebo irrespective of whether they had 
moderate or severe pain at baseline [78]. Pregabalin was also significantly better than placebo 
in patients with a range of comorbid conditions at baseline including osteoarthritis (450 
mg/day only) [87], headache [88], immune problems or allergies [88], gastroesophageal 
reflux disease [88], insomnia [88], depression [88], irritable bowel syndrome (450 mg/day 
only) [88], neurological conditions [88], asthma [88], and symptoms of anxiety or depression 
[89]. Prior opioid use is not a barrier to significant pain relief with pregabalin [90], and nor is 
tender point severity [91]. The magnitude of the pain response may depend on age, pain 
severity, and sleep score at baseline, with greater improvements in those with more severe 
baseline pain and sleep, and older patients [92]. A post-hoc analysis of patients with FM 
taking an selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinepherine reuptake 
inhibitor (SNRI) for comorbid depression [93] demonstrated that pregabalin was significantly 
better than placebo irrespective of age, body mass index, FM duration since diagnosis, short-
term depression (<10 years), FM as the first diagnosis, number of previous FM medications, 
depression diagnosis, use of a low dose of antidepressant, presence of headache or 
osteoarthritis, prior opioid use, baseline pain severity, presence of moderately severe FM, 
anxiety severity, and sleep disruption severity. 
 
Safety 
A small number of post-hoc analyses focused on safety data. In a pooled analysis of three 
studies, the efficacy of pregabalin was assessed in those patients who reported somnolence as 
an AE [94]. The effect of pregabalin on pain relief, patient function, and sleep disturbance 
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was comparable between those patients with and without somnolence. An analysis of patients 
who reported weight gain as an AE indicated that patients with FM had a mean weight gain 
of 2.0 kg (median 1.7 kg), or a mean percent weight gain from baseline of 2.7% (median 
2.5%) [95].  
 
Discussion  
This evidence-based summary evaluated the efficacy and safety of pregabalin for FM as 
demonstrated in double-blind, randomized, controlled clinical studies, open-label extensions 
of these clinical studies, meta-analyses, combination studies, and post-hoc analyses. In 
placebo-controlled clinical studies, pregabalin consistently demonstrates significant 
improvements versus placebo in pain, sleep, and patient function at doses of 300–600 
mg/day. These findings are supported by multiple sets of meta-analyses. Combination studies 
show that pregabalin is efficacious when used with other pharmacotherapies. Post-hoc 
analyses have shown that the improvements in FM symptoms occur as early as 1–2 days of 
starting treatment, that pregabalin also improves other aspects of sleep beyond quality, and 
that the analgesic effects of pregabalin occur irrespective of a wide variety of patient 
demographic and clinical characteristics at baseline. These studies also show that pregabalin 
has a well-established safety and tolerability profile, with rates of discontinuations due to 
AEs and incidences of AEs increasing dose-dependently. The safety and tolerability data 
from the individual studies are again supported by meta-analyses. Dizziness and somnolence 
are the most common AEs reported irrespective of pregabalin dose, and withdrawals due to 
AEs are more frequent for pregabalin over placebo. 
 
The majority of clinical studies were in adults, but one was in adolescents up to 17 years of 
age [52]. In comparison with the adult studies, pregabalin did not significantly improve pain 
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scores at endpoint compared with placebo in adolescents, although the magnitude of response 
was numerically similar to adults. Some secondary endpoints were significantly better with 
pregabalin versus placebo, including the proportion of PGIC responders, and most endpoints 
were numerically better than placebo. The safety profile was consistent with that seen in 
adults. The discrepancies between adults and adolescents may have occurred because the 
adolescent study struggled to recruit subjects, and only 107 patients were eventually included. 
Pregabalin may have more closely replicated efficacy outcomes in adults in a larger sample 
population.  
 
The magnitude of the placebo-adjusted pain response on the 11-point NRS ranged from –0.33 
to –0.98 for doses of 300 or 450 mg/day. The clinical relevance of this effect has been 
questioned [63], but individual patient responses should also be considered [96], as 
recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical 
Trials (IMMPACT) [97]. As revealed by the 30% and 50% pain responder analyses, 
pregabalin produces clinically relevant improvements in pain [84] in up to half of patients. 
Moreover, up to half of patients were PGIC responders, i.e., they reported their symptoms as 
being very much or much improved by pregabalin. As well as being efficacy endpoints in the 
randomized, placebo-controlled studies, pain responder rates were also the main efficacy 
endpoint of interest for most of the meta-analyses. The findings from the meta-analyses 
confirmed the findings from the randomized, placebo-controlled studies, showing that pain 
responder rates were higher for pregabalin over placebo irrespective of dose. PGIC responder 
rates were also assessed in some of the meta-analyses. Again, the data from the meta-analyses 
support the randomized, placebo-controlled studies, showing that PGIC responder rates are 
higher for pregabalin over placebo irrespective of dose. As well as statistically and clinically 
significant improvements in pain, the positive effects of pregabalin on other FM symptoms, 
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notably disrupted sleep, should also be taken into account [96]. Improvements in pain and 
sleep can appear as early as 1–2 days after starting treatment [82]. The efficacy of pregabalin 
demonstrated in the clinical studies is supported by multiple meta-analyses of different 
efficacy endpoints. The consistency in findings across the meta-analyses reflects the fact that 
a core number of pregabalin studies were included in each meta-analysis. Nonetheless, it is 
encouraging that different sets of authors all reached the same conclusions. 
 
Data from the randomized, placebo-controlled studies and the open-label extension studies 
show that pregabalin has a consistent safety profile across those studies. Although open-label 
studies are not as rigorous as randomized, controlled studies, in this instance the data from 
the open-label studies provide additional valuable information on the longer-term safety 
profile of pregabalin. Dizziness and somnolence were the most commonly reported AEs 
[42,43,45-48,51]. Some of the commonest AEs (dizziness, somnolence, weight gain, and 
constipation) may appear within 4 weeks of starting treatment [85], and may last for weeks or 
longer [42,43]. As a result, discontinuations due to AEs occur in up to a quarter of adult 
patients receiving doses of 300 or 450 mg/day pregabalin [42,43,45-48,51]. Although safety 
data were not statistically compared in the randomized, placebo-controlled clinical studies, 
withdrawal rates due to AEs were statistically compared in some of the meta-analyses. These 
data show that withdrawals due to AEs occurs significantly more often for pregabalin over 
placebo, irrespective of dose. In general, the incidences of AEs and discontinuations due to 
AEs are dose dependent, which highlights the potential importance of titrating patients to the 
maximally tolerated therapeutic dose. The parallel group or crossover clinical studies of 
pregabalin included a titration period of 1–3 weeks [42,43,45-48,51,52], but we can 
hypothesize that a longer titration period may improve tolerability early in treatment. 
Although there are no practical data to support this, in clinical practice titration is typically 
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slower than that seen in clinical trials. The goal should be to reach therapeutic doses based on 
the evidence presented here.  
 
Current product labeling recommends pregabalin dosing twice daily, with the dose equally 
divided [34]. Studies examining different dosing schedules are rare, but in the single 
randomized controlled trial that examined this subject [55], once-nightly dosing appeared to 
confer some safety and tolerability advantages over twice-daily dosing, with no effect on 
efficacy. Future studies that identify new and appropriate dosing regimens are an important 
area of research. 
 
Studies examining the clinical effects of pregabalin in combination with other 
pharmacotherapies has not received much attention. Indeed, our searches identified only 7 
combination studies, of which only 2 were randomized, controlled studies. We therefore also 
assessed data from other studies, including open-label and retrospective studies. Our findings 
show that pregabalin demonstrates efficacy in combination with other pharmacotherapies, 
and indicates it might be useful as part of a polypharmacy regimen. Many patients may 
benefit from multi-drug treatment, but the data are limited. Pregabalin may also be beneficial 
as part of a multimodal therapeutic approach, i.e., pharmacological and non-pharmacological 
treatments, but again this has not been adequately studied. Patients with FM have multiple 
symptoms and functional impairment, so clinicians need to be realistic about how useful 
single pharmacotherapies can be. Combination pharmacotherapy and multimodal treatment of 
FM is an area ripe for future study. 
 
A review [1] of worldwide FM epidemiology described different prevalence rates across 
different countries, highlighting that FM is a global problem that has taken many years to 
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recognize. To date, pregabalin is approved for the treatment of FM in the US [34], Japan, and 
37 other countries, underscoring the need for viable treatment options that can help to address 
the needs of patients worldwide. Most of the pregabalin clinical studies discussed here were 
based in the US, although several international studies have been conducted [46,48,50-52], 
and a study specifically in Japanese patients was performed [47].  A study in Chinese patients 
has recently completed although data are pending. As shown in this review, the safety and 
tolerability profile of pregabalin was similar among US, international, and Japanese patients, 
highlighting its utility in different geographic populations. 
 
This review is an evidence-based clinical summary of pregabalin efficacy and safety, and as 
such is associated with some limitations. Not all the data summarized were from randomized, 
controlled trials or systematic reviews and meta-analyses. Publication bias was not assessed 
despite all the randomized, placebo-controlled studies being industry sponsored. 
Nevertheless, we have included findings from both positive and negative studies, and 
reported data on both positive and negative efficacy endpoints. Limitations associated with 
the individual clinical studies may also be important and should be considered. Most of the 
studies lasted for several weeks, but FM is a long-lasting, chronic condition [24]. Safety data 
were not statistically compared. Pregabalin was assessed as monotherapy only, but 
polypharmacy is more likely in the real world. As noted above, titration periods lasted from 1 
to 3 weeks, whereas titration may be slower in practice. Each study also had specific patient 
inclusion and exclusion criteria. Post-hoc analyses were limited to the patients that 
participated in the clinical trials identified, and the data that were captured as part of those 
trials.  
 
Conclusions 
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The purpose of this evidence-based review was to summarize the clinical data supporting the 
use of pregabalin for the treatment of FM. Data from randomized, placebo-controlled studies 
have demonstrated its efficacy and safety for the treatment of FM pain as well as multiple 
other symptoms, including sleep disruption, patient status, and to a lesser extent patient 
function, fatigue, anxiety, and depression. Some patients have clinically meaningful 
responses, for instance improvements in 30% and 50% pain responder rates. The clinical 
study data are supported by multiple meta-analyses. Combining pregabalin with other 
pharmacotherapies may be beneficial. Post-hoc analyses have further examined the clinical 
utility of pregabalin for FM. The safety profile of pregabalin is well established and 
consistent across clinical studies for all populations analyzed, including adolescents. The 
most common AEs are dizziness and somnolence. Pregabalin continues to be a viable 
treatment option for FM-related pain and other FM symptoms. The information provided here 
may help physicians and other healthcare professionals make an informed decision when 
considering pregabalin for their patients with FM. 
 
Transparency section 
Declaration of funding 
Authors received no funding in the preparation of this article. 
 
Declaration of financial/other relationships 
Dr Lesley Arnold has performed consulting services for Pfizer Inc, Daiichi Sankyo, 
Innovative Med Concepts, Zynerba Pharmaceuticals Inc, Eli Lilly & Company, CinRx and 
Astellas, participated on speaker bureau for Pfizer Inc, and received research support from Eli 
Lilly & Company, Cefaly, Daiichi Sankyo, Allergan, Tonix, and Pfizer Inc. Dr Ernest Choy 
has served as a member of advisory boards and on speaker bureau for Pfizer. Dr Daniel 
   
   
26 
 
Clauw has performed consulting services for Pfizer Inc, Eli Lilly & Company, Pierre Fabre 
Laboratories, Aptinyx Inc, Cerephex Corporation, IMC Pharma, Zynerba Pharmaceuticals 
Inc, and Samumed LLC, and received research support from Pfizer Inc, Forest Laboratories, 
and Cerephex Corporation. Ed Whalen, David Semel, Lynne Pauer, and Lloyd Knapp are 
employees of Pfizer, and have stocks or stock options in Pfizer. Dr Hiroshi Oka has no 
conflicts of interest to declare. 
 
Author contributions  
All authors were involved in the conception of this article; in the drafting of the article and 
for critically revising it for intellectual content; approved the final version to be published; 
and agree to be accountable for all aspects of the work. 
 
Acknowledgments 
We thank Andrew Clair of Pfizer for initial discussions on potential topics for review. 
Medical writing support was provided by David Cope, PhD, of Engage Scientific Solutions, 
and funded by Pfizer. 
 
  
  
   
   
27 
 
References 
1. Queiroz LP. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep. 
2013;17;(8):356. 
2. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of 
fibromyalgia in the general population. Arthritis Rheum. 1995;38;(1):19-28. 
3. Wolfe F, Brähler E, Hinz A, et al. Fibromyalgia prevalence, somatic symptom 
reporting, and the dimensionality of polysymptomatic distress: results from a survey of the 
general population. Arthritis Care Res (Hoboken). 2013;65;(5):777-785. 
4. Vincent A, Lahr BD, Wolfe F, et al. Prevalence of fibromyalgia: a population-based 
study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis 
Care Res (Hoboken). 2013;65;(5):786-792. 
5. Branco JC, Bannwarth B, Failde I, et al. Prevalence of fibromyalgia: a survey in five 
European countries. Semin Arthritis Rheum. 2010;39;(6):448-453. 
6. Haq SA, Darmawan J, Islam MN, et al. Prevalence of rheumatic diseases and 
associated outcomes in rural and urban communities in Bangladesh: a COPCORD study. J 
Rheumatol. 2005;32;(2):348-353. 
7. Guermazi M, Ghroubi S, Sellami M, et al. [Fibromyalgia prevalence in Tunisia]. 
Tunis Med. 2008;86;(9):806-811. 
8. Senna ER, De Barros AL, Silva EO, et al. Prevalence of rheumatic diseases in Brazil: 
a study using the COPCORD approach. J Rheumatol. 2004;31;(3):594-597. 
9. White KP, Speechley M, Harth M, et al. The London Fibromyalgia Epidemiology 
Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol. 
1999;26;(7):1570-1576. 
10. McNally JD, Matheson DA, Bakowsky VS. The epidemiology of self-reported 
fibromyalgia in Canada. Chronic Dis Can. 2006;27;(1):9-16. 
   
   
28 
 
11. Mas AJ, Carmona L, Valverde M, et al. Prevalence and impact of fibromyalgia on 
function and quality of life in individuals from the general population: results from a 
nationwide study in Spain. Clin Exp Rheumatol. 2008;26;(4):519-526. 
12. Topbas M, Cakirbay H, Gulec H, et al. The prevalence of fibromyalgia in women 
aged 20-64 in Turkey. Scand J Rheumatol. 2005;34;(2):140-144. 
13. Clauw DJ. Fibromyalgia and related conditions. Mayo Clin Proc. 2015;90;(5):680-
692. 
14. Gracely RH, Petzke F, Wolf JM, et al. Functional magnetic resonance imaging 
evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46;(5):1333-
1343. 
15. Cook DB, Lange G, Ciccone DS, et al. Functional imaging of pain in patients with 
primary fibromyalgia. J Rheumatol. 2004;31;(2):364-378. 
16. Napadow V, LaCount L, Park K, et al. Intrinsic brain connectivity in fibromyalgia is 
associated with chronic pain intensity. Arthritis Rheum. 2010;62;(8):2545-2555. 
17. Napadow V, Kim J, Clauw DJ, et al. Decreased intrinsic brain connectivity is 
associated with reduced clinical pain in fibromyalgia. Arthritis Rheum. 2012;64;(7):2398-
2403. 
18. Jensen KB, Loitoile R, Kosek E, et al. Patients with fibromyalgia display less 
functional connectivity in the brain's pain inhibitory network. Mol Pain. 2012;8:32. 
19. Harris RE, Sundgren PC, Craig AD, et al. Elevated insular glutamate in fibromyalgia 
is associated with experimental pain. Arthritis Rheum. 2009;60;(10):3146-3152. 
20. Foerster BR, Petrou M, Edden RA, et al. Reduced insular gamma-aminobutyric acid 
in fibromyalgia. Arthritis Rheum. 2012;64;(2):579-583. 
   
   
29 
 
21. Harris RE, Sundgren PC, Pang Y, et al. Dynamic levels of glutamate within the insula 
are associated with improvements in multiple pain domains in fibromyalgia. Arthritis Rheum. 
2008;58;(3):903-907. 
22. Lopez-Sola M, Woo CW, Pujol J, et al. Towards a neurophysiological signature for 
fibromyalgia. Pain. 2017;158;(1):34-47. 
23. Mease PJ, Arnold LM, Crofford LJ, et al. Identifying the clinical domains of 
fibromyalgia: contributions from clinician and patient Delphi exercises. Arthritis Rheum. 
2008;59;(7):952-960. 
24. Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311;(15):1547-1555. 
25. Schaefer C, Chandran A, Hufstader M, et al. The comparative burden of mild, 
moderate and severe fibromyalgia: results from a cross-sectional survey in the United States. 
Health Qual Life Outcomes. 2011;9:71. 
26. Perrot S, Schaefer C, Knight T, et al. Societal and individual burden of illness among 
fibromyalgia patients in France: association between disease severity and OMERACT core 
domains. BMC Musculoskelet Disord. 2012;13:22. 
27. Schaefer C, Mann R, Masters ET, et al. The Comparative Burden of Chronic 
Widespread Pain and Fibromyalgia in the United States. Pain Pract. 2016;16;(5):565-579. 
28. Robinson RL, Kroenke K, Mease P, et al. Burden of illness and treatment patterns for 
patients with fibromyalgia. Pain Med. 2012;13;(10):1366-1376. 
29. Hauser W, Walitt B, Fitzcharles MA, et al. Review of pharmacological therapies in 
fibromyalgia syndrome. Arthritis Res Ther. 2014;16;(1):201. 
30. Lauche R, Cramer H, Häuser W, et al. A Systematic Overview of Reviews for 
Complementary and Alternative Therapies in the Treatment of the Fibromyalgia Syndrome. 
Evid Based Complement Alternat Med. 2015;2015:610615. 
   
   
30 
 
31. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of 
pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for 
antiepileptic drug discovery. Epilepsy Res. 2007;73;(2):137-150. 
32. Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca(2+) influx by 
gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002;42;(2):229-
236. 
33. Cunningham MO, Woodhall GL, Thompson SE, et al. Dual effects of gabapentin and 
pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci. 
2004;20;(6):1566-1576. 
34. Lyrica® Prescribing Information. [Internet]. New York, NY: Pfizer Inc; 2016. 
Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=561 [Last accessed June 8, 
2016]. 
35. Cymbalta® Prescribing Information. [Internet]. Indianapolis, IN: Lilly USA, LLC; 
2016. Available from: http://pi.lilly.com/us/cymbalta-pi.pdf [Last accessed September 21, 
2016]. 
36. Savella® Prescribing Information. [Internet]. Irvine, CA: Allergan USA, Inc; 2016. 
Available from: http://www.allergan.com/assets/pdf/savella_pi [Last accessed September 21, 
2016]. 
37. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the 
management of fibromyalgia. Ann Rheum Dis. 2017;76;(2):318-328. 
38. Fitzcharles MA, Ste-Marie PA, Goldenberg DL, et al. 2012 Canadian Guidelines for 
the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res 
Manag. 2013;18;(3):119-126. 
39. Sommer C, Häuser W, Alten R, et al. [Drug therapy of fibromyalgia syndrome. 
Systematic review, meta-analysis and guideline]. Schmerz. 2012;26;(3):297-310. 
   
   
31 
 
40. Ablin JN, Amital H, Ehrenfeld M, et al. [Guidelines for the diagnosis and treatment of 
the fibromyalgia syndrome]. Harefuah. 2013;152;(12):742-747, 751, 750. 
41. Ablin J, Fitzcharles MA, Buskila D, et al. Treatment of fibromyalgia syndrome: 
recommendations of recent evidence-based interdisciplinary guidelines with special emphasis 
on complementary and alternative therapies. Evid Based Complement Alternat Med. 
2013;2013:485272. 
42. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of 
fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. 
Arthritis Rheum. 2005;52;(4):1264-1273. 
43. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-
controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J 
Rheumatol. 2008;35;(3):502-514. 
44. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and 
efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-
controlled trial with pregabalin. Pain. 2008;136;(3):419-431. 
45. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, 
placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 
2008;9;(9):792-805. 
46. Pauer L, Winkelmann A, Arsenault P, et al. An international, randomized, double-
blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients 
with fibromyalgia. J Rheumatol. 2011;38;(12):2643-2652. 
47. Ohta H, Oka H, Usui C, et al. A randomized, double-blind, multicenter, placebo-
controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients 
with fibromyalgia. Arthritis Res Ther. 2012;14;(5):R217. 
   
   
32 
 
48. Roth T, Lankford DA, Bhadra P, et al. Effect of pregabalin on sleep in patients with 
fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way 
crossover polysomnography study. Arthritis Care Res (Hoboken). 2012;64;(4):597-606. 
49. Harris RE, Napadow V, Huggins JP, et al. Pregabalin rectifies aberrant brain 
chemistry, connectivity, and functional response in chronic pain patients. Anesthesiology. 
2013;119;(6):1453-1464. 
50. Arnold LM, Arsenault P, Huffman C, et al. Once daily controlled-release pregabalin 
in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized 
withdrawal, placebo-controlled study. Curr Med Res Opin. 2014;30;(10):2069-2083. 
51. Arnold LM, Sarzi-Puttini P, Arsenault P, et al. Efficacy and Safety of Pregabalin in 
Patients with Fibromyalgia and Comorbid Depression Taking Concurrent Antidepressant 
Medication: A Randomized, Placebo-controlled Study. J Rheumatol. 2015;42;(7):1237-1244. 
52. Arnold LM, Schikler KN, Bateman L, et al. Safety and efficacy of pregabalin in 
adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-
month open-label extension study. Pediatr Rheumatol Online J. 2016;14;(1):46. 
53. Arnold LM, Emir B, Murphy TK, et al. Safety profile and tolerability of up to 1 year 
of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia. Clin 
Ther. 2012;34;(5):1092-1102. 
54. Ohta H, Oka H, Usui C, et al. An open-label long-term phase III extension trial to 
evaluate the safety and efficacy of pregabalin in Japanese patients with fibromyalgia. Mod 
Rheumatol. 2013;23;(6):1108-1115. 
55. Nasser K, Kivitz AJ, Maricic MJ, et al. Twice daily versus once nightly dosing of 
pregabalin for fibromyalgia: a double-blind randomized clinical trial of efficacy and safety. 
Arthritis Care Res (Hoboken). 2014;66;(2):293-300. 
   
   
33 
 
56. Hauser W, Bernardy K, Uçeyler N, et al. Treatment of fibromyalgia syndrome with 
gabapentin and pregabalin--a meta-analysis of randomized controlled trials. Pain. 
2009;145;(1-2):69-81. 
57. Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in 
adults. Cochrane Database Syst Rev. 2009;(3):CD007076. 
58. Hauser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, 
milnacipran, and pregabalin in fibromyalgia syndrome. J Pain. 2010;11;(6):505-521. 
59. Straube S, Derry S, Moore RA, et al. Pregabalin in fibromyalgia: meta-analysis of 
efficacy and safety from company clinical trial reports. Rheumatology (Oxford). 
2010;49;(4):706-715. 
60. Tzellos TG, Toulis KA, Goulis DG, et al. Gabapentin and pregabalin in the treatment 
of fibromyalgia: a systematic review and a meta-analysis. J Clin Pharm Ther. 
2010;35;(6):639-656. 
61. Choy E, Marshall D, Gabriel ZL, et al. A systematic review and mixed treatment 
comparison of the efficacy of pharmacological treatments for fibromyalgia. Semin Arthritis 
Rheum. 2011;41;(3):335-345 e336. 
62. Roskell NS, Beard SM, Zhao Y, et al. A meta-analysis of pain response in the 
treatment of fibromyalgia. Pain Pract. 2011;11;(6):516-527. 
63. Nuesch E, Häuser W, Bernardy K, et al. Comparative efficacy of pharmacological and 
non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann 
Rheum Dis. 2013;72;(6):955-962. 
64. Zaccara G, Perucca P, Gangemi PF. The adverse event profile of pregabalin across 
different disorders: a meta-analysis. Eur J Clin Pharmacol. 2012;68;(6):903-912. 
65. Üçeyler N, Sommer C, Walitt B, et al. Anticonvulsants for fibromyalgia. Cochrane 
Database Syst Rev. 2013;(10):CD010782. 
   
   
34 
 
66. Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and 
fibromyalgia - an overview of Cochrane reviews. Cochrane Database Syst Rev. 
2013;(11):CD010567. 
67. Derry S, Cording M, Wiffen PJ, et al. Pregabalin for pain in fibromyalgia in adults. 
Cochrane Database Syst Rev. 2016;9:CD011790. 
68. Lee YH, Song GG. Comparative efficacy and tolerability of duloxetine, pregabalin, 
and milnacipran for the treatment of fibromyalgia: a Bayesian network meta-analysis of 
randomized controlled trials. Rheumatol Int. 2016;36;(5):663-672. 
69. Calandre EP, Morillas-Arques P, Rodriguez-Lopez CM, et al. Pregabalin 
augmentation of quetiapine therapy in the treatment of fibromyalgia: an open-label, 
prospective trial. Pharmacopsychiatry. 2007;40;(2):68-71. 
70. Calandre EP, Morillas-Arques P, Molina-Barea R, et al. Trazodone plus pregabalin 
combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled 
study. BMC Musculoskelet Disord. 2011;12:95. 
71. Metyas S, Ibrahim M, Ortiz EC, et al. Monotherapy versus combination therapy in the 
treatment of fibromyalgia. Ann Rheum Dis. 2013;71;(Suppl 3):276. 
72. Gilron I, Chaparro LE, Tu D, et al. Combination of pregabalin with duloxetine for 
fibromyalgia: a randomized controlled trial. Pain. 2016;157;(7):1532-1540. 
73. Mease PJ, Farmer MV, Palmer RH, et al. Milnacipran combined with pregabalin in 
fibromyalgia: a randomized, open-label study evaluating the safety and efficacy of adding 
milnacipran in patients with incomplete response to pregabalin. Ther Adv Musculoskelet Dis. 
2013;5;(3):113-126. 
74. Del Giorno R, Skaper S, Paladini A, et al. Palmitoylethanolamide in Fibromyalgia: 
Results from Prospective and Retrospective Observational Studies. Pain Ther. 
2015;4;(2):169-178. 
   
   
35 
 
75. Ramzy EA. Comparative Efficacy of Newer Antidepressants in Combination with 
Pregabalin for Fibromyalgia Syndrome: A Controlled, Randomized Study. Pain Pract. 
2017;17;(1):32-40. 
76. Straube S, Derry S, Moore RA, et al. Pregabalin in fibromyalgia--responder analysis 
from individual patient data. BMC Musculoskelet Disord. 2010;11:150. 
77. Parsons B, Argoff CE, Clair A, et al. Improvement in pain severity category in 
clinical trials of pregabalin. J Pain Res. 2016;9:779-785. 
78. Clair A, Emir B. The safety and efficacy of pregabalin for treating subjects with 
fibromyalgia and moderate or severe baseline widespread pain. Curr Med Res Opin. 
2016;32;(3):601-609. 
79. Roth T, Bhadra-Brown P, Pitman VW, et al. Pregabalin Improves Fibromyalgia-
related Sleep Disturbance. Clin J Pain. 2016;32;(4):308-312. 
80. Peterson BT, Resnick M, Brosnan M, et al. Effect of pregabalin on home sleep and 
daytime activity patterns in patients with fibromyalgia and sleep maintenance difficulties. 
Sleep. 2011;34:A232. 
81. Russell IJ, Crofford LJ, Leon T, et al. The effects of pregabalin on sleep disturbance 
symptoms among individuals with fibromyalgia syndrome. Sleep Med. 2009;10;(6):604-610. 
82. Arnold LM, Emir B, Pauer L, et al. Time to improvement of pain and sleep quality in 
clinical trials of pregabalin for the treatment of fibromyalgia. Pain Med. 2015;16;(1):176-185. 
83. Bushmakin AG, Cappelleri JC, Chandran AB, et al. Evaluation of the fibromyalgia 
impact questionnaire at baseline as a predictor for time to pain improvement in two clinical 
trials of pregabalin. Int J Clin Pract. 2013;67;(1):52-59. 
84. Farrar JT, Young JP, Jr., LaMoreaux L, et al. Clinical importance of changes in 
chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 
2001;94;(2):149-158. 
   
   
36 
 
85. Parsons B, Emir B, Clair A. Temporal analysis of pain responders and common 
adverse events: when do these first appear following treatment with pregabalin. J Pain Res. 
2015;8:303-309. 
86. Pauer L, Atkinson G, Murphy TK, et al. Long-term maintenance of response across 
multiple fibromyalgia symptom domains in a randomized withdrawal study of pregabalin. 
Clin J Pain. 2012;28;(7):609-614. 
87. Argoff CE, Emir B, Whalen E, et al. Pregabalin Improves Pain Scores in Patients with 
Fibromyalgia Irrespective of Comorbid Osteoarthritis. Pain Med. 2016;17;(11):2100-2108. 
88. Bhadra P, Petersel D. Medical conditions in fibromyalgia patients and their 
relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials. Expert Opin 
Pharmacother. 2010;11;(17):2805-2812. 
89. Arnold LM, Leon T, Whalen E, et al. Relationships among pain and depressive and 
anxiety symptoms in clinical trials of pregabalin in fibromyalgia. Psychosomatics. 
2010;51;(6):489-497. 
90. Argoff CE, Clair A, Emir B, et al. Prior Opioid Use Does Not Impact the Response to 
Pregabalin in Patients With Fibromyalgia. Clin J Pain. 2016;32;(7):555-561. 
91. Starz T, Wilson H, Robinson J, et al. The effect of baseline tender point severity on 
treatment outcome in pregabalin clinical trials. J Pain. 2010;11:S37. 
92. Emir B, Murphy TK, Petersel DL, et al. Treatment response to pregabalin in 
fibromyalgia pain: effect of patient baseline characteristics. Expert Opin Pharmacother. 
2010;11;(14):2275-2280. 
93. Silverman SL, Backonja M, Pauer L, et al. Effect of Baseline Characteristics on the 
Pain Response to Pregabalin in Fibromyalgia Patients with Comorbid Depression. Pain Med. 
2017 [Epub ahead of print]. 
   
   
37 
 
94. Pauer L, Gary A, Petersel DL, et al. The effect of somnolence on pain, function, and 
sleep responses to pregabalin in patients with fibromyalgia. Arthritis Rheum. 2009;60;(Suppl 
10):93. 
95. Cabrera J, Emir B, Dills D, et al. Characterizing and understanding body weight 
patterns in patients treated with pregabalin. Curr Med Res Opin. 2012;28;(6):1027-1037. 
96. Arnold LM, Cappelleri JC, Clair A, et al. Interpreting effect sizes and clinical 
relevance of pharmacological interventions for fibromyalgia. Pain Ther. 2013;2;(1):65-71. 
97. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of 
treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 
2008;9;(2):105-121. 
98. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 
1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria 
Committee. Arthritis Rheum. 1990;33;(2):160-172. 
99. Yunus MB, Masi AT. Juvenile primary fibromyalgia syndrome. A clinical study of 
thirty-three patients and matched normal controls. Arthritis Rheum. 1985;28;(2):138-145. 
100. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology 
preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. 
Arthritis Care Res (Hoboken). 2010;62;(5):600-610. 
   
   
38 
 
Table 1. Summary of placebo-controlled clinical studies, meta-analyses, and combination studies of pregabalin for fibromyalgia  
Study type Objective Entry criteria References 
Placebo-controlled 
clinical studies 
   
Parallel group Efficacy and safety 
Pregabalin-naïve adults with FMa without painful disorders that may 
confound assessment of FM pain and not taking prohibited pain or sleep 
medications, except acetaminophen 
[42,43,45-47] 
Adolescents (12–17 years old) with FMb without painful disorders that may 
confound assessment of FM pain and not taking certain prohibited pain or 
sleep medications, except acetaminophen, NSAIDs, coxibs, zolpidem, or 
eszopiclone  
[52] 
Randomized 
withdrawal 
Efficacy and safety 
Adults with FMa without painful disorders that may confound assessment of 
FM pain 
[44,50] 
Crossover Efficacy and safety Adults with FMa taking an SSRI or SNRI for comorbid depression [51] 
PSG 
Effects on PSG 
measures of sleep 
Adults with FMa and disturbed sleep despite normal sleep-wake schedule 
with no active sleep disorder, except insomnia disorder, and no history of any 
[48] 
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sleep or circadian rhythm sleep disorder in the past 5 years 
Neuroimaging 
Identify clinical action 
of pregabalin 
Right-handed adults with FMa without painful disorders that may confound 
assessment of FM pain, and able to complete the neuroimaging procedures 
[49] 
Meta-analyses 
Efficacy 
Randomized, placebo-controlled studies 
[58,61,63,65,66]  
Tolerability [64] 
Efficacy and 
tolerability 
[57,59,60,62,67] 
Combination 
therapy 
Efficacy and safety 
together with 
duloxetine or 
milnacipran 
i. Patients with FM 
ii. Adults with FMa and without a distinct condition of similar or greater 
pain severity than FM 
iii. Adults with FMa with incomplete response to pregabalin 
[71-73]  
Efficacy and safety 
together with other 
medications 
i. Adult female patients with FM taking quetiapine for ≥6 months 
ii. Patients with FMa taking trazadone for ≥12 weeks 
iii. Patients with FM taking duloxetine plus pregabalin for 6 months and 
administered PEA 
[69,70,74,75] 
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iv. Female adults with FMc taking pregabalin and randomized to an 
antidepressant 
FM = fibromyalgia; NSAID = non-steroidal anti-inflammatory drug; PEA = palmitoylethanolamide; PSG = polysomnography; SNRI = 
serotonin/norepinephrine reuptake inhibitor; SSRI = serotonin-selective reuptake inhibitor. 
aFM diagnostic criteria detailed in reference [98]. 
bFM diagnostic criteria detailed in reference [99]. 
cFM diagnostic criteria detailed in reference [100]. 
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Table 2. Summary of efficacy results from the randomized, double-blind, placebo-controlled clinical studies  
Study 
Dose 
(mg/kg) 
Domain 
Pain Sleep Status Function 
Fatigue 
Mood 
Mean 
Score LTR 
30%  
Responders 
50% 
Responders Quality WASO 
PGIC 
Responders FIQ Anxiety Depression 
Adults 
Crofford et 
al. 2005 [42] 
150            
300     ü   ü   ü    
450 ü    ü  ü   ü   ü    
Mease et al. 
2008 [43] 
300 ü     ü   ü      
450 ü     ü   ü      
600 ü     ü   ü      
Crofford et 
al. 2008 [44] 
All  ü           
Arnold et al. 300 ü   ü  ü  ü   ü      
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Table 3. Summary of safety and tolerability results from the randomized, double-blind, 
placebo-controlled clinical studies  
Study 
Pregabalin dose 
(mg/day) 
All-causality treatment-emergent AEs, % 
Patients with 
AEs 
Patients with 
SAEs 
Discontinuations 
due to AEs 
Crofford et al. 
2005 [42] 
Placebo 77.1 0.8 7.6 
150 78.0 0 8.3 
300 88.1 2.2 7.5 
450 91.7 0.8 12.9 
Mease et al. 
2008 [43] 
Placebo 76.3 2.1 10.5 
300 89.2 3.2 18.9 
450 91.8 1.1 22.4 
600 93.7 1.1 32.6 
Crofford et al. 
2008 [44] 
All dosesa 82.1 0.8 18.6 
Arnold et al. 
2008 [45] 
Placebo 71.7 1.1 10.9 
300 80.9 1.1 16.4 
450 88.4 1.1 21.6 
600 88.3 1.1 26.1 
Pauer et al. 
2011 [46] 
Placebo 73.4 2.2 10.9 
300 84.8 1.1 19.0 
450 90.1 4.4 19.8 
600 91.9 2.2 25.8 
Ohta et al. Placebo 70.6 0.4 3.6 
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2012 [47] All dosesb 90.0 1.2 9.6 
Roth et al. 
2012 [48] 
Placebo 29.7 0 0.9 
All dosesc 65.2 0 1.8 
Arnold et al. 
2014 [50] 
All dosesa 80.0 1.1 12.2 
Arnold et al. 
2015 [51] 
Placebo 59.9 0.6 3.4 
All dosesb 77.3 1.7 6.1 
Arnold et al. 
2016 [52] 
Placebo 64.2 0 7.5 
All dosesd 70.4 1.9 7.4 
AEs = adverse events; SAEs = serious adverse events. 
aDetermined during the single-blind treatment phase only.  
bPregabalin data are for doses of 300 and 450 mg/day combined. 
cPregabalin data are for doses of 150, 300, and 450 mg/day combined. 
dPregabalin data are for doses of 75, 150, 300, and 450 mg/day combined. 
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Figure 1. Placebo-adjusted mean pain scores, sleep quality scores, and proportion of 
PGIC responders at the end of treatment in the parallel group and crossover studies by 
study and by pregabalin dose  
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(A,B) Error bars are the 95% confidence intervals. Dotted line indicates no change versus 
placebo. Key in (A) also applies to (B). Sleep quality was scored on an 11-point NRS in all 
studies. For Crofford et al. 2005, Mease et al. 2008, Arnold et al. 2008, Pauer et al. 2011, 
Ohta et al. 2012, and Arnold et al. 2016, scores ranged from 0 = best possible sleep to 10 = 
worst possible sleep. For Roth et al. 2012 and Arnold et al. 2015, scores ranged from 0 = 
worst possible sleep to 10 = best possible sleep. For the purpose of consistent interpretation 
of the data, Roth et al. 2012 and Arnold et al. 2015 have been reversed so that the 
directionality is the same as for the other studies. PGIC responders were defined as those 
patients whose FM symptoms were ‘much improved’ or ‘very much improved’ at the end of 
treatment. Data in Ohta et al. 2012 and Arnold et al. 2015 are for doses of 300 and 450 
mg/day combined. Data in Roth et al. 2012 are for doses of 150, 300, and 450 mg/day 
combined. Mean pain scores and sleep quality scores at study endpoint were not evaluated for 
this study; data are for week 4 of active treatment. Data in Arnold et al. 2016 are for doses of 
75, 150, 300, and 450 mg/day combined. Note that Roth et al. 2012, Harris et al. 2013, and 
Arnold et al. 2015 are 2-way crossover studies. Data from the 2 treatment periods in these 
studies were combined to produce a single data point. * p < 0.05, ** p < 0.01, and *** p < 
0.001 versus placebo. 
LS = least squares; NRS = numeric rating scale; PGIC = Patient Global Impression of 
Change. 
 
